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INTRODUCTION
Advantages of umbilical cord blood transplantation
(UCBT) include rapid availability, tolerance of 0-to-2 HLA-
antigen disparity, and potentially decreased rates of severe
acute and chronic graft-versus-host disease (GVHD) [1-4].
Although there have been a few reports of Epstein-Barr
virus–associated posttransplantation lymphoproliferative
disorders (EBV-PTLD) after UCBT [5,6], the risk of this
complication has not been reported. Furthermore, although
both innate and stimulated immunity to EBV have been
demonstrated in UCB lymphocytes [7-9], the true capacity
of naive neonatal T cells to regulate EBV-associated lym-
phoproliferation is uncertain. To further investigate the risk
of EBV-PTLD after UCBT, we reviewed the outcomes of
272 unrelated-donor UCB transplantations performed at
the University of Minnesota and Duke University Medical
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ABSTRACT
Umbilical cord blood (UCB) is being increasingly used for transplantation, but the ability of neonatal T cells to
regulate Epstein-Barr virus (EBV)-associated lymphoproliferation is unknown. Because UCB transplantation
(UCBT) is associated with a relatively low infused dose of donor T cells, frequent donor-recipient HLA disparity,
and use of antithymocyte globulin during conditioning, we hypothesized that the risk of EBV-associated post-
transplantation lymphoproliferative disorders (EVB-PTLD) after UCBT may be increased. To investigate the
incidence of EBV-PTLD after UCBT, we analyzed 272 unrelated-donor UCBTs performed from August 1993 to
December 1999 at Duke University Medical Center and the University of Minnesota. Five cases of EBV-PTLD
were identified, with a cumulative incidence of 2% (95% confidence interval, 0.3%-3.7%) at 2 years. EBV-PTLD
affected UCB recipients aged 1 to 49 years (median, 8 years), with 4 patients undergoing transplantation for
leukemia and 1 for immunodeficiency. Patients received UCB grafts that were HLA matched (n = 1) or mis-
matched at 1 (n = 1) or 2 (n = 3) HLA loci. Diagnoses occurred at 4 to 14 months (median, 6 months) after UCBT,
with 4 of 5 patients having preceding grade II to IV acute graft-versus-host disease and 1 being diagnosed at
autopsy. Treatment of 4 patients consisted of withdrawal of immunosuppressive treatment and administration of
rituximab, with 2 of 4 patients responding. Thus, the incidence of EBV-PTLD after unrelated-donor UCBT
appears similar to that observed after transplantation using unrelated bone marrow (BM) and compares favorably
with unrelated-donor T-cell–depleted BM transplantation. Because adoptive immunotherapy with donor lympho-
cytes is not an available option for recipients of unrelated-donor UCBT, new therapeutic strategies are needed,
and rituximab appears promising.
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Center. Herein the clinical features of affected patients and
the cumulative incidence of EBV-PTLD are reported.
METHODS
Patients
All patients who had undergone unrelated-donor UCBT
at the University of Minnesota (n = 68) and Duke University
Medical Center (n = 204) with a minimum of 6 months fol-
low-up were eligible for analysis. Patients underwent trans-
plantation from August 1993 to December 1999, and data
analysis was performed as of December 2000. Patients
received UCB units with 0 to 3 HLA-A, -B, -DRB1 mis-
matches obtained from the Placental Blood Programs at the
New York Blood Center, the St. Louis Cord Blood Bank,
COBLT (Cord Blood Transplantation Study), and through
Netcord. Patient diagnoses included acute leukemia,
myelodysplasia (MDS), chronic myelogenous leukemia, bone
marrow (BM) failure syndromes, immunodeficiency disor-
ders, hemoglobinopathies, and inborn errors of metabolism.
For all patients, HLA-A and -B typing was determined by
serology, whereas HLA-DRB1 allele–level typing was deter-
mined by high-resolution molecular techniques. Treatment
protocols were reviewed and approved by the Institutional
Review Boards of both institutions and written informed
consent was obtained from all subjects or their guardians.
Conditioning and GVHD Prophylaxis
Sixty-one percent of patients were conditioned with a
1320 to 1375 cGy fractionated total body irradiation–based
regimen with chemotherapy and 39% with a myeloablative
combination chemotherapy–based regimen. Patients with
Fanconi anemia received a dose-reduced preparative regi-
men [10]. All UCB recipients received antithymocyte glob-
ulin (ATG), 30 mg/kg per day on days –3 to –1. GVHD
prophylaxis consisted of cyclosporine and methylpred-
nisone as previously described [1,2].
EBV-PTLD Diagnosis
Diagnoses were made by biopsies of involved tissues dur-
ing life in patients 2 to 5 and postmortem in patient 1, with
pathological classiﬁcation according to internationally recog-
nized criteria using routine histology and immunohisto-
chemistry for B-cell markers including CD20, immuno-
globulin light chains, and EBV-associated antigens [11].
Additional ﬂow cytometry for lineage and clonality analysis,
molecular studies for immunoglobulin heavy-chain gene
rearrangement, EBV genome, and restriction-fragment
length polymorphisms were performed on patient biopsy
specimens from patients 2 and 3 [11]. The diagnosis of EBV-
PTLD in patients 4 and 5 was supported by detection of
diagnostic levels of the EBV genome in the peripheral blood
using semiquantative polymerase chain reaction methodol-
ogy as per McDiarmid et al. [12], with unique primers devel-
oped by Memorial Sloan Kettering Cancer Center used for
patient 5 (V. Prasad, oral communication, April 2001).
Statistical Analysis
The estimate of EBV-PTLD was expressed as a cumula-
tive incidence [13]. Death without EBV-PTLD was treated
as a competing risk.
RESULTS
Five cases (Minnesota, n = 3; Duke, n = 2) of EBV-PTLD
were identiﬁed for a cumulative incidence of 2% (95% conﬁ-
dence interval, 0.3%-3.7%) at 2 years. EBV-PTLD affected
UCB recipients aged 1 to 49 years (median, 8 years), with
4 patients receiving transplants for leukemia/ advanced MDS
and 1 for congenital immunodeficiency. Patients received
UCB grafts, which were HLA matched (n = 1) or mismatched
at 1 (n = 1) or 2 (n = 3) HLA loci, after a number of different
conditioning regimens, all of which contained ATG. Each
patient achieved myeloid engraftment prior to day 35 with
complete donor chimerism and no evidence of recurrent dis-
ease. All patients were undergoing treatment for GVHD
when EBV-PTLD developed (3 for acute GVHD and 2 for
chronic GVHD preceded by acute). Therapy for GVHD
consisted of either cyclosporine or FK506 (tacrolimus) and
corticosteroids in 4 patients, with 1 patient receiving multiple
immunosuppressant therapies (Table 1).
The characteristics of the EBV-PTLD are summarized in
Table 2. Diagnosis of EBV-PTLD occurred at 4 to 14 months
(median, 6 months) after UCBT, with 1 patient being diag-
nosed at autopsy. Four of 5 patients had disseminated dis-
ease. EBV-PTLD pathology varied from polymorphic (n = 4)
to monomorphic (n = 1), with all cases being positive for
B-cell markers including CD20. The diagnosis of EBV-
PTLD, made by clinical manifestations and biopsy of
involved tissue, was further supported by very high copy
numbers of the EBV genome in 2 patients (patients 4 and 5)
[14-18]. The malignant tissue was clonal and of donor ori-
gin in 2 of 2 patients tested (patients 2 and 3).
Treatment of 4 patients consisted of reduction in
immunosuppression and intravenous (IV) rituximab,
375 mg/m2 per dose weekly for 1 to 3 doses. Patient 2
received additional therapy with acyclovir, 10 mg/kg IV
every 8 hours; α-interferon 1,000,000 U/d subcutaneously
for 3 days (withdrawn due to rapidly progressing pancytope-
nia); and cytotoxic chemotherapy (vincristine, 2 mg IV, and
methylprednisolone, 1 g IV, on day 7; adriamycin, 25 mg/m2
IV, cyclophosphamide, 750 mg/m2, and vincristine, 1.5 mg
IV, on day 12; and methylprednisolone, 200 mg/d, on days
12-16) without response. Two of 4 patients responded to
therapy at a median follow-up of 14 months, whereas
2 failed to demonstrate significant response despite being
CD20 positive. These 2 patients died of EBV-PTLD and
sepsis/organ failure.
DISCUSSION
PTLD, usually of B-cell origin, can manifest as a wide
spectrum of abnormal lymphoid proliferation, from poly-
clonal reactive hyperplasia to polymorphic PTLD to
monomorphic lymphoma, usually of the diffuse large cell
type [11]. It is well established that infection with EBV plays
a major role in PTLD etiology, and direct incorporation of
the EBV genome into the abnormal lymphoid tissue can
often be demonstrated. This herpes-group virus infects 95%
of the population by adulthood, with latent virus persisting
within B lymphocytes. It is proposed that immunosuppres-
sion, particularly defective cytotoxic T-cell function, permits
EBV reactivation and the uncontrolled proliferation of
EBV-driven B cells [16].
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PTLD after BM transplantation (BMT) is usually a
rapidly lethal complication, occurring predominantly in the
first 6 months [19]. A review of 18,014 allogeneic BMT
patients by Curtis et al. reported a cumulative PTLD inci-
dence of 1% at 10 years [19], whereas 2% of allogeneic
BMT cases were complicated by PTLD in a Minnesota
series [20]. A review by the National Marrow Donor Pro-
gram of the outcomes of 5075 recipients of unrelated-donor
BMTs who received GVHD prophylaxis with either
immunosuppressive therapy alone (n = 3785) or T-cell
depletion (TCD) of donor BM (n = 1290) revealed a 2-year
incidence of EBV-PTLD of 1% ± 1% with immunosup-
pression compared to a 6% ± 2% incidence in recipients of
TCD BMTs [21].
In the review by Curtis et al., risk factors strongly asso-
ciated with PTLD after BMT were unrelated donor or
≥2 HLA–mismatched related donor, TCD of donor BM,
and use of ATG or anti-CD3 antibody for prophylaxis/treat-
Table 1. Clinical Characteristics of Unrelated-Donor UCBT Recipients with EBV-PTLD*
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age, y 7 49 49 8 1
Diagnosis Relapsed AML Accelerated- Advanced MDS Secondary AML Wiskott-Aldrich
(prior autoBMT) phase CML syndrome
Nucleated cell dose† 2.9 × 107 1.2 × 107 1.6 × 107 4.1 × 107 8.9 × 107
T-cell dose‡ 4.2 × 106 2.1 × 106 1.4 × 106 3.6 × 106 6.4 × 106
HLA match 6/6 5/6 4/6 4/6 4/6
Conditioning TBI 1320 cGy, TBI 1320 cGy, TBI 1320 cGy, TBI 1250 cGy, Bu 480 mg/m2,
Cy 120 mg/kg, Cy 120 mg/kg, Cy 120 mg/kg, Mel 135mg/m2, Cy 200 mg/kg,
ATG ATG ATG ATG ATG
GVHD type (grade) Acute: skin Acute: skin, Acute: upper Acute: skin (I) Acute: skin,
(II)/chronic upper gut (II) gut (II) liver(IV)/chronic
GVHD therapy CSA/steroids CSA/steroids CSA/steroids FK506/steroids FK506/steroids/
dacluzimab/
azothioprine
*UCBT indicates umbilical cord blood transplant; EBV-PTLD, Epstein-Barr virus–associated posttransplanation lymphoproliferative disorder;
AML, acute myeloid leukemia; auto-BMT, autologous bone marrow transplantation; CML, chronic myelogenous leukemia; MDS, myelodysplasia;
TBI, total body irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; Mel, melphalan; Bu, busulphan; GVHD, graft-versus-host dis-
ease; CSA, cyclosporine A; steroids, corticosteroids; FK506, tacrolimus.
†Cryopreserved cell dose per kilogram recipient body weight.
‡Infused cell dose per kilogram recipient body weight.
Table 2. Characteristics of EBV-PTLD in Unrelated-Donor UCBT Recipients*
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Diagnosis† 14 mo 4 mo 5 mo 6 mo 9 mo
Pathology Polymorphous Monomorphic Polymorphous Polymorphous Polymorphous
B cell/EBV+ B cell/EBV+ B cell/EBV+ B cell/EBV+ B cell/EBV+
Clonality: NA Monoclonal Monoclonal Clonality: NA Clonality: NA
Origin: donor Origin: donor PB EBV+++‡ PB EBV+++‡
Sites of disease LA: chest, abdomen Widespread LA Stomach  LA: neck, chest Widespread LA
Lungs Upper gut Single abdo LN Lungs Gut
Abdo organs Spleen Lungs
Therapy None (diagnosis Acyclovir/α-IFN, Reduced IS, Reduced IS, Reduced IS,
at autopsy) reduced IS, rituximab rituximab (2)§ rituximab (1)§ rituximab (2)§
(3)§, chemotherapy
Outcome Death due to: Death due to: Remission Remission Death due to:
GVHD, infection, pneumonitis (follow-up: 13 mo) (follow-up: 15 mo) GVHD, infection,
EBV-PTLD (idiopathic), EBV-PTLD EBV-PTLD
*EBV-PTLD indicates Epstein-Barr virus–associated posttransplanation lymphoproliferative disorder; UCBT, umbilical cord blood transplant;
NA, not available; PB, peripheral blood; LA, lymphadenopathy; abdo, abdominal; LN, lymph node; IFN, interferon; IS, immunosuppression;
GVHD, graft-versus-host disease.
†Time from UCBT to EBV-PTLD diagnosis.
‡Polymerase chain reaction for EBV DNA performed on PB.
§Rituximab given at 375 mg/m2. Number in parentheses indicates number of doses given at weekly intervals.
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ment of acute GVHD. A weaker association with grades II
to IV acute GVHD was found, although extensive chronic
GVHD acted as a risk factor for late-onset EBV-PTLD
[19]. The risk associated with TCD of HLA-mismatched
related or HLA-matched unrelated donors is supported by
the high cumulative EBV-PTLD incidences of 5% to 25%
in recipients of such transplants [22]. The other series have
found TCD, transplantation for immunodeficiency, and
donor age to be the most signiﬁcant risk factors [20,21].
Application of these risk factors after BMT to unre-
lated-donor UCBT may predict an increased risk of EBV-
PTLD in UCBT due to the relatively low donor T-cell
dose, frequent donor-recipient HLA disparity, and use of
ATG during conditioning. Conversely, a potential advantage
may be that nearly all neonatal donors are EBV negative,
thus reducing the risk from transfer of EBV-infected lym-
phocytes within the graft [23]. Also, UCBT recipients may
be at an advantage by virtue of a relatively reduced likeli-
hood of severe acute and extensive chronic GVHD [1-4].
Fortunately, this series does not suggest a greatly
increased incidence of EBV-PTLD after unrelated-donor
UCBT. In fact, the incidence compares favorably with the
incidences reported after unrelated-donor BMT with TCD
[21,22]. Because 1 patient had EBV-PTLD detected at
autopsy, it is always possible that other cases have remained
undiagnosed. However, this issue applies equally to the esti-
mated incidence after transplantation with other sources. Also,
the 2 centers in this study practice close long-term follow-up
of their patients, facilitating diagnosis of complications even if
late in the posttransplantation course. It is notable that 4 of
the 5 UCBT patients developed EBV-PTLD in the context of
grades II to IV acute GVHD, with all patients on immuno-
suppression at disease onset and the 2 patients with relatively
late-onset disease both having chronic GVHD.
How immune recovery after UCBT compares with that
after transplantation of hematopoietic stem cells from other
sources is only just beginning to be investigated. Thomson
et al. reported a numerical recovery of T cells at 9 to
12 months, of B cells at 6 months, and of natural killer
(NK) cells at 2 months after transplantation [24]. Although
the recovery of CD8+ T cells was thought to be delayed
compared with that seen after transplantation with other
sources of hematopoietic stem cells, no difference in func-
tional immune recovery was documented. Weinberg et al.
have shown that UCBT recipients have no evidence of
decreased T-cell receptor excision circles, despite continua-
tion of immunosuppressive drugs [25]. In regard to EBV-
specific immunity, Marshall et al. reported undetectable
EBV-speciﬁc T cells in 4 UCBT recipients [26]. However,
EBV viral titers were not elevated in these patients. Fur-
thermore, Moretta et al. have shown that the innate immu-
nity against EBV in UCB is in fact mediated by CD4+ and
NK cells [7]. Also, Early et al. have demonstrated more
rapid transformation of naive CD4+ T cells to effector cells
in newborns than adults, which may counteract diminished
primary T-cell responses [27]. Finally, EBV-specific
immune effectors may be induced in vitro [8,9], and in vivo
correlates of such events may mediate EBV-speciﬁc immu-
nity in the UCBT recipient.
Adoptive immunotherapy with donor leukocytes has
been cited by some as the most effective therapy for BMT-
associated EBV-PTLD. In 1994, Papadopoulos et al.
reported use of unmanipulated leukocytes from the original
EBV-seropositive donors [28]. To avoid GVHD, Heslop et al.
have generated EBV-speciﬁc cytotoxic T lymphocytes and
have demonstrated their efficacy in both prophylaxis and
therapy of EBV-PTLD [29]. However, unrelated-donor
UCBT precludes therapy with donor leukocytes unless
T cells are removed from the graft preinfusion. Although ex
vivo expansion of UCB T cells is being investigated [30],
other treatment strategies are needed.
The most promising new alternative therapy for EBV-
PTLD is the anti-CD20 chimeric monoclonal antibody
rituximab [31]. Kuehnle et al. recently described successful rit-
uximab therapy of EBV-PTLD in 3 BMT patients [17]. Milpied
et al. have documented complete remission in 5 of 6 BMT
patients after rituximab therapy in a retrospective study, with
prolonged survival in 4 patients [32]. Therefore, rituximab,
combined with reduction in immunosuppression if applicable,
may be a successful therapy for some UCBT patients as sug-
gested by the response in 2 of 4 patients in this report. Prog-
nostic factors for the treatment of EBV-PTLD with murine
anti–B-cell monoclonal antibodies have been described [33],
but such information is not currently known for rituximab.
McGuirk et al. reported use of irradiated haploidentical
donor lymphocytes in combination with rituximab to control
EBV-PTLD after haploidentical BMT with TCD [34]. The
relative value of each of these therapies in this case is unclear,
although allogeneic leukocytes have been used as therapy for
solid organ–associated PTLD [35]. Therefore, an experimen-
tal approach to therapy for UCBT patients not responding to
rituximab alone could be irradiated lymphocytes from alter-
native adult EBV-seropositive donors and rituximab. Another
potential approach would be preemptive therapy with ritux-
imab in those patients demonstrating high levels of the EBV
genome in the peripheral blood prior to the onset of clinical
manifestations of disease [18]. Greater experience is required
to determine if this use of rituximab will be warranted on a
cost-beneﬁt basis, but such treatment could be a considera-
tion in unrelated-donor UCBT patients with GVHD.
In summary, the incidence of EBV-PTLD after unrelated-
donor UCBT appears similar to that seen after transplanta-
tion of allogeneic hematopoietic stem cells from other
sources and compares favorably with the incidence of EBV-
PTLD reported after unrelated-donor BMT with TCD.
For those UCBT patients who do develop this complica-
tion, new attention should be directed toward developing
alternative treatment strategies.
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